July 6, 2020

Study Examines Racial Disparities in PCI Outcomes

July 6, 2020—The American College of Cardiology (ACC) announced the publication of a study showing that Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major adverse outcomes, including death, compared with White patients. According to ACC, the study underscores the high rates of cardiovascular disease and risk factors in minorities and the continued need for further research on race-based outcomes after cardiovascular procedures, including PCI, to understand and alleviate these differences.

Mordechai Golomb, MD, et al published the findings in Journal of the American College of Cardiology: Cardiovascular Interventions (2020; 13:1586–1595).

“The variables that may contribute to the greater cardiovascular risks in minorities are multifactorial,” commented senior investigator Gregg W. Stone, MD, in the ACC announcement. “The variables include risk factors (eg, greater hypertension, smoking and diabetes, and differences in body mass index), differences in cardiac structure (eg, coronary artery size and left ventricular mass), and socioeconomic considerations (eg, reduced access to care and/or insurance coverage, lack of preventative care, disease awareness and education, delayed presentation when ill, and in some studies varying provision of care).”

As noted by ACC, racial differences in cardiovascular outcomes were first reported several decades ago. Blacks consistently have higher rates of cardiovascular risk factors and adverse outcomes compared with non-Hispanic Whites, and both Blacks and Hispanics have been associated with increased risk of cardiovascular diseases.

Previous studies have suggested that short- and long-term outcomes after PCI vary by race and cannot be fully explained by different baseline risk factors and treatment characteristics, but other studies have failed to show a significant association. Furthermore, because current raced-based PCI outcomes have been acquired from registries and single-center studies lacking central monitoring and event adjudication, the investigators of this study sought to assess the presence of racial disparities in clinical characteristics and outcomes from a large patient-level pooled database.

In this study, investigators used data from the Cardiovascular Research Foundation to analyze 10 prospective, randomized controlled trials with a combined total of 22,638 patients classified by race who underwent PCI. There were 20,585 (90.9%) White patients (reference group), 918 (4.1%) Black patients, 404 (1.8%) Asian patients, and 473 (2.1%) Hispanic patients. Other races were excluded from the analysis due to small sample sizes.

The investigators assessed baseline characteristics such as body mass index and PCI outcomes at 30 days, 1, and 5 years. Principal outcomes of interest were all-cause death; myocardial infarction (MI); and major adverse cardiac events (MACE) defined as the composite of cardiac death, MI, or ischemia-driven target lesion revascularization.

In the 5-year follow-up after PCI, MACE rates were 23.9% in Black patients, 18.8% in White patients, 21.5% in Hispanic patients, and 11.2% in Asian patients.

Multivariable analysis demonstrated an independent association between Black patients and 5-year risk of MACE following PCI. Black patients also had higher rates of death at both the 1- and 5-year follow-up after PCI compared with any other group. Results from the analysis showed that while enrolled in PCI, both Black and Hispanic patients had greater cardiovascular risk factors including diabetes, hypertension, and hyperlipidemia than White and Asian patients.

“I am inherently optimistic, and I am hopeful that the increased societal attention to racial disparities prompted by recent social injustices will translate to improve health care and outcomes for minorities,” Dr. Stone said. “But it won’t just happen without active concerted efforts to promote change and opportunity, a task for government, regulators, payors, hospital administrators, physicians, and all health care providers.”

The study’s limitations were outlined in the ACC announcement. These include: Black and Hispanic patients were underrepresented in the trials so there is a potential for some selection bias; socioeconomic factors were not captured, which may influence differences in the risk of adverse outcomes after PCI; and the term “Hispanic” was designated as a race and not ethnicity, thereby potentially limiting the differences in outcomes between Hispanics and other races. Because this study included racial disparities in the three largest minority groups, further studies are required to address other minority groups and ethnicities/subgroups.

Dr. Stone noted, “Achieving representative proportions of minorities in clinical trials is essential but has proven challenging. We must ensure that adequate numbers of hospitals and providers that are serving these patients participate in multicenter trials, and trust has to be developed so that minority populations have the confidence to enroll in studies. Language can be a barrier, requiring translation services and extra time and effort. Involvement of the families and primary care physicians who have an established relationship with patients in clinical trial discussions is useful. Finally, enrollment of non-Hispanic whites can be capped at a certain proportion of the total to ensure adequate enrollment of other racial and ethnic groups.”

In an accompanying editorial comment, Eric D. Peterson, MD, MPH, Professor of Medicine in the Division of Cardiology at Duke University School of Medicine, said the study findings serve as a reminder of how large the racial gaps in cardiovascular disease treatments and outcomes are and continue to be. He commented, “Solving racial health disparities is a crucial and pressing priority for all in health care. We must all commit to reversing racial health disparities for tomorrow’s generation. Talking is no longer enough; it is our responsibility to finally deliver effective solutions.”


July 6, 2020

Ten-Year Follow-Up Reported From a Single-Center Experience With Early TAVR Devices

July 1, 2020

Findings Published From Initial United States Experience With Abiomed Impella 5.5 With SmartAssist